Halo Pharma Simplifies Topical Drug Product Development and Manufacturing

Apr 12, 2018
By Pharmaceutical Technology Editors

On April 12, 2018, Halo Pharma announced that it will discuss its capabilities in topical drug products at CPhI North America, taking place April 24–26, 2018 in Philadelphia, PA, at booth 1549.

The company’s experience includes more than 30 years of producing a range of top drug products, including prescription dermatological drugs to over-the-counter and high-value health and beauty products. Halo Pharma has topical centers of excellence in its Whippany, NJ, and Mirabel, Quebec, Canada, facilities that provide a one-stop-shop for global pharmaceutical companies looking to develop and manufacture compliant, high-quality gels, creams, lotions, and sterile and non-sterile ointments for a range of indications, as stated by the company.

According to Research and Markets, global sales of topical drug products are predicted to reach $194.2 billion by 2024. Halo Pharma notes that these drugs target localized skin sites or offer systemic penetration by formulations that are easily applied and conveniently packaged and  are complex to formulate because they typically mix oil and water phases in various ratios with an active pharmaceutical ingredient and other ingredients to create a semi-solid or liquid formulation that is safe, efficacious, and patient friendly.

Halo Pharma reports that because it can formulate, develop, scale up, manufacture, and package topical drug products in contiguous, end-to-end production areas, it eliminates unnecessary changes in process and equipment, as well as knowledge gaps, that can occur when topical products are transferred.

For more information and to register for the event, visit www.cphinorthamerica.com.

Source: Halo Pharma

native1_300x100
lorem ipsum